Prospective open label proof of concept feasibility interventional clinical trial in which 60
acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in
addition to Standard Of Care Peginterferon + Ribavirin if they show a Rapid Viral Responds at
week 4.
The primary hypothesis of this study is that the subset of patients with a Rapid Viral
Responds after 4 weeks of triple therapy with boceprevir, peginterferon alpha-2b (P) and
ribavirin (RVR4) can be successfully treated with a shorter 12-week triple therapy regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Erasmus Medical Center
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Maastricht University Medical Center Onze Lieve Vrouwe Gasthuis Radboud University Rijnstate Hospital Slotervaart Hospital UMC Utrecht University Medical Center Groningen